As of 2025-03-27, the EV/EBITDA ratio of Cardiff Oncology Inc (CRDF) is -4.88. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Cardiff's latest enterprise value is 235.48 mil USD. Cardiff's TTM EBITDA according to its financial statements is -48.29 mil USD. Dividing these 2 quantities gives us the above Cardiff EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.1x - 12.2x | 12.1x |
| Forward P/E multiples | 15.1x - 27.8x | 16.4x |
| Fair Price | (10.95) - (8.87) | (10.34) |
| Upside | -409.2% - -350.6% | -392.2% |
| Date | EV/EBITDA |